Sydney, Australia 27 November 2024 –At Omico, collaboration and data-driven insights are core to our mission to advance cancer care. Through the ASPiRATION study*, we have partnered with the Thoracic Oncology Group of Australasia (TOGA), NHMRC Clinical Trials Centre (CTC), University of Sydney, and industry partners, supported by the Australian Government’s Medical Research Future Fund (MRFF) and Roche Products  Pty. Limited. Together, we are exploring the impact of comprehensive genomic profiling (CGP) and precision medicine for metastatic lung cancer—a disease with a challenging five-year survival rate of only 17%.

* ASPiRATION: assessing the impact of genomic profiling in lunch cancer; MRFF funding awarded 2020: https://www.grants.gov.au/Ga/Show/9198f839-d56f-bfd4-3a76-b246a53c4c31

The ASPiRATION Study: A Milestone in Precision Medicine
ASPiRATION is Australia’s first observational cohort study assessing CGP’s role in newly diagnosed metastatic non-small cell lung cancer patients. One thousand patients across 16 hospitals were enrolled from December 2020 to June 2023. The study aims to assess the impact of CGP to personalise treatment options and improve patient outcomes, gaining quality of life insights over time.

With ASPiRATION, we are building a unique, high-quality real-world dataset that hopes to shape future approaches in lung cancer treatment. The contributions of patients and clinicians, along with the commitment from industry and government stakeholders, have been fundamental in working towards robust longitudinal data collection to date.

Key Insights and the Power of Patient Follow-Up Data

Achieving high-quality follow-up data in oncology research is notoriously challengingOmico’s Clinical Follow Up team has worked tirelessly to gather detailed data, achieving impressive results to date:

• High Data Completion Rates: We have achieved over 95% data collection on key data.
• Extensive Follow-Up Efforts: Thanks to the dedicated Clinical Follow-Up team, there have been over 5,000 attempts to follow up, leveraging various channels across hospitals, admin teams, and individual practitioners. Some patients remain under active surveillance for treatment selection, though less than 2% of patients currently unaccounted for, whilst data collection is continuing — a testament to the dedication of all involved.
• Quality of Life Data:  QOL data is also being collected at regular timepoints, which in future may offer insights into quality-of-life outcomes during the treatment journey.
• Unexpected Findings: Of interest, some patients did not start systemic therapy before passing away, prompting further exploration into factors influencing this outcome.

 Collaboration for Future Discoveries

ASPiRATION exemplifies the impact of collaboration across the healthcare sector. With ongoing PhD projects through The University of Sydney, data analyses underway at the CTC, and translational research projects commencing under the scientific oversight of TOGA, ASPiRATION’s longitudinal data opens new avenues for research in metastatic lung cancer.

Acknowledging Patients and Clinicians

We extend our deepest thanks to the patients and clinicians who have dedicated time, energy, and resources to make ASPiRATION possible.

Their contributions form the foundation of this impactful research and provide hope and direction for future advances. We look forward to the ongoing discoveries this collaboration will bring, as Omico and its partners continue advancing precision oncology to optimise outcomes for all Australians.